Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;38(1):e113-e116.
doi: 10.1111/jdv.19464. Epub 2023 Aug 29.

A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)

L Gargiulo  1   2 , L Ibba  1   2 , P Malagoli  3 , F Amoruso  4 , G Argenziano  5 , A Balato  5 , F Bardazzi  6 , M Burlando  7 , C G Carrera  8 , G Damiani  9   10 , P Dapavo  11 , V Dini  12 , G Fabbrocini  13 , C Franchi  10 , F M Gaiani  3 , G Girolomoni  14 , C Guarneri  15 , C Lasagni  16 , F Loconsole  17 , A V Marzano  8   18 , M Maurelli  14 , M Megna  13 , D Orsini  19 , F Sampogna  20 , M Travaglini  21 , M Valenti  1   2 , A Costanzo  1   2 , A Narcisi  1
Affiliations

A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)

L Gargiulo et al. J Eur Acad Dermatol Venereol. 2024 Jan.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661. https://doi.org/10.1016/S0140-6736(18)31713-6
    1. Gargiulo L, Ibba L, Pavia G, Vignoli CA, Piscazzi F, Valenti M, et al. Real-life effectiveness and safety of Risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309-2324. https://doi.org/10.1007/s13555-022-00795-x
    1. Gkalpakiotis S, Cetkovska P, Arenberger P, Dolezal T, Arenbergerova M, Velackova B, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from The Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345-1355. https://doi.org/10.1007/s13555-021-00556-2
    1. Orsini D, Gargiulo L, Ibba L, Cascio Ingurgio R, Valenti M, Perugini C, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatolog Treat. 2023;34(1):2220849. https://doi.org/10.1080/09546634.2023.2220849
    1. Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157:1-78. https://doi.org/10.23736/S2784-8671.21.07132-2

LinkOut - more resources